Other

Linda B Whittall

Grayson Walker Stowell

Robert R Whittle

Frederick D Sancilio

Douglas John Jenkins

Glenn A Meyer

Steven A Fontana

The present invention provides processes for purifying 6-methoxy omeprazole, products using such processes, pharmaceutical formulations using such products, and methods of using such products for gastric acid inhibition.

Process for purifying 6-methoxy omeprazole

Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.

Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same

Dry blend pharmaceutical formulations

Granulated pharmaceutical formulations and methods for making the same

The present invention provides dry blend pharmaceutical formulations in unit dosage forms comprising per dosage unit one or more active pharmaceutical ingredients or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof wherein the ratio of said one or more active pharmaceutical ingredients in said formulations is essentially the same as the ratio of said active pharmaceutical ingredients in the corresponding, non-formulated drug substance and, wherein said formulations in unit dosage form are adapted for oral administration.

Dry blend pharmaceutical unit dosage form

Pharmaceutical compositions and formulations comprised of one or more active ingredients or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof combined with at least one cyclodextrin.

Pharmaceutical formulations

Improved bioavailability method of one or more of certain pharmaceutically active compounds or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof that include administering a non-toxic, therapeutically effective amount of the compounds combined with at least one cyclodextrin to a mammal in need of treatment of gastric acid related diseases.

Method of improving bioavailability

Pharmaceutical formulations, in oral unit dosage forms, have one or more active ingredients or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof combined with at least one cyclodextrin.

Pharmaceutical unit dosage form

The present invention provides pharmaceutical formulations comprising compositions one or more of certain active pharmaceutical ingredients or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof wherein the ratio of said one or more active pharmaceutical ingredients in said formulations is essentially the same as the ratio of said active pharmaceutical ingredients in the corresponding, non-formulated drug substance. Methods for using the same are included.

Compounds of the formula (Ia) are disclosed by the invention, along with compositions thereof optionally in combination with compounds of formulae (Ib). Methods of making and using the same are also disclosed.

Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same

Pharmaceutical oral unit dosage forms are comprised of, per dosage unit, one or more active ingredients or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof.

Growing community of inventors

Wilmington, NC, United States of America

Linda B Whittall